[Form 4] Co-Diagnostics, Inc. Insider Trading Activity
James B. Nelson, a director of Co-Diagnostics, Inc. (CODX), was granted 125,000 restricted stock units (RSUs) on 08/13/2025. Each RSU converts to one share of common stock upon vesting, and the award shows 103,333 underlying shares currently attributable, producing 228,333 shares beneficially owned after the grant. The RSUs carry a $0.00 price and vest in six equal installments beginning 11/23/2025 and continuing every six months thereafter. The grant was reported on a Form 4 filed by the reporting person as an individual.
James B. Nelson, membro del consiglio di Co-Diagnostics, Inc. (CODX), ha ricevuto 125.000 unit脿 di azioni vincolate (RSU) il 13/08/2025. Ogni RSU si converte in una azione ordinaria al momento del vesting, e l'assegnazione indica 103.333 azioni sottostanti attualmente attribuibili, per un totale di 228.333 azioni possedute beneficiariamente dopo la concessione. Le RSU hanno un prezzo di $0,00 e maturano in sei rate uguali a partire dal 23/11/2025, con scadenze successive ogni sei mesi. La concessione 猫 stata segnalata in un Modulo 4 depositato dalla persona che ha effettuato la comunicazione a titolo individuale.
James B. Nelson, director de Co-Diagnostics, Inc. (CODX), recibi贸 125.000 unidades de acciones restringidas (RSU) el 13/08/2025. Cada RSU se convierte en una acci贸n ordinaria al consolidarse, y la adjudicaci贸n muestra 103.333 acciones subyacentes actualmente atribuibles, sumando 228.333 acciones de propiedad beneficiosa tras la adjudicaci贸n. Las RSU tienen un precio de $0,00 y se consolidan en seis cuotas iguales a partir del 23/11/2025, continuando cada seis meses. La concesi贸n fue informada en un Formulario 4 presentado por la persona informante a t铆tulo individual.
Co-Diagnostics, Inc. (CODX) 鞚挫偓鞚� James B. Nelson鞚� 2025-08-13鞐� 125,000欤检潣 鞝滍暅欤检嫕雼渼(RSU)毳� 攵�鞐皼鞎橃姷雼堧嫟. 臧� RSU電� 氩犾姢韺� 鞁� 氤错喌欤� 1欤茧 鞝勴櫂霅橂┌, 鞚措矆 靾橃棳電� 順勳灛 攴�靻嶋悩電� 103,333欤检潣 旮办磮 欤检嫕鞚� 響滌嫓頃橃棳 靾橃棳 頉� 齑� 228,333欤�鞚� 鞁れ 氤挫湢毳� 齑堧灅頃╇媹雼�. RSU鞚� 臧�瓴╈潃 $0.00鞚措┌ 2025-11-23攵�韯� 鞁滌瀾頃� 齑� 6須岇棎 瓯胳硱 霃欖澕頃� 牍勳湪搿� 氩犾姢韺呺悩瓿� 鞚错泟 6臧滌洈毵堧嫟 瓿勳啀霅╇媹雼�. 鞚� 靾橃棳電� 氤搓碃鞚胳澊 臧滌澑 鞛愱博鞙茧 鞝滌稖頃� Form 4鞐� 氤搓碃霅橃棃鞀惦媹雼�.
James B. Nelson, administrateur de Co-Diagnostics, Inc. (CODX), s'est vu accorder 125 000 unit茅s d'actions restreintes (RSU) le 13/08/2025. Chaque RSU se convertit en une action ordinaire lors de l'acquisition, et l'attribution indique 103 333 actions sous-jacentes actuellement imputables, portant le total 脿 228 333 actions d茅tenues 脿 titre b茅n茅ficiaire apr猫s l'attribution. Les RSU ont un prix de 0,00 $ et s'acqui猫rent en six tranches 茅gales 脿 partir du 23/11/2025, puis tous les six mois. L'attribution a 茅t茅 d茅clar茅e dans un formulaire 4 d茅pos茅 par la personne d茅clarante 脿 titre individuel.
James B. Nelson, Vorstand bei Co-Diagnostics, Inc. (CODX), erhielt am 13.08.2025 125.000 Restricted Stock Units (RSUs). Jede RSU wandelt sich bei Vesting in eine Stammaktie um, und die Zuteilung weist derzeit 103.333 zugrundeliegende Aktien aus, wodurch sich nach der Zuteilung insgesamt 228.333 Aktien im wirtschaftlichen Besitz ergeben. Die RSUs haben einen Preis von $0,00 und vesten in sechs gleichen Tranchen beginnend am 23.11.2025, danach alle sechs Monate. Die Zuteilung wurde in einem Formular 4 gemeldet, das die meldende Person als Einzelperson eingereicht hat.
- Transparent disclosure of the RSU grant and resulting beneficial ownership on Form 4
- Time-based vesting aligns director incentives with long-term shareholder value
- No cash outlay required from the director; grant is equity-based compensation
- Potential future dilution from 125,000 RSUs if all vest and convert into shares
- No performance conditions disclosed beyond time-based vesting in this filing
Insights
TL;DR Routine director equity grant for compensation; modest dilution and standard multi-period vesting, neutral near-term financial impact.
The 125,000 RSU award is a typical equity-based compensation instrument used to align director incentives with shareholders. The grant's $0.00 price and multi-period vesting reduce immediate dilution concerns because shares are contingent on future vesting. The reported underlying share count and total beneficial ownership provide transparency on immediate ownership concentration. There is no cash transaction and no exercise price exposure. This filing does not disclose performance conditions beyond time-based vesting.
TL;DR Standard governance practice: time-based RSU award to a director with staggered vesting; aligns long-term interests without immediate liquidity events.
The grant follows common governance norms: RSUs granted under the 2015 Long Term Incentive Plan, vesting over multiple installments beginning in late 2025. Reporting as a director-held award offers clarity on insider holdings and reduces concerns about opportunistic insider sales tied to the grant. The Form 4 provides required disclosure on beneficial ownership post-transaction. No indication of accelerated vesting, change-in-control provisions, or performance hurdles is provided in this filing.
James B. Nelson, membro del consiglio di Co-Diagnostics, Inc. (CODX), ha ricevuto 125.000 unit脿 di azioni vincolate (RSU) il 13/08/2025. Ogni RSU si converte in una azione ordinaria al momento del vesting, e l'assegnazione indica 103.333 azioni sottostanti attualmente attribuibili, per un totale di 228.333 azioni possedute beneficiariamente dopo la concessione. Le RSU hanno un prezzo di $0,00 e maturano in sei rate uguali a partire dal 23/11/2025, con scadenze successive ogni sei mesi. La concessione 猫 stata segnalata in un Modulo 4 depositato dalla persona che ha effettuato la comunicazione a titolo individuale.
James B. Nelson, director de Co-Diagnostics, Inc. (CODX), recibi贸 125.000 unidades de acciones restringidas (RSU) el 13/08/2025. Cada RSU se convierte en una acci贸n ordinaria al consolidarse, y la adjudicaci贸n muestra 103.333 acciones subyacentes actualmente atribuibles, sumando 228.333 acciones de propiedad beneficiosa tras la adjudicaci贸n. Las RSU tienen un precio de $0,00 y se consolidan en seis cuotas iguales a partir del 23/11/2025, continuando cada seis meses. La concesi贸n fue informada en un Formulario 4 presentado por la persona informante a t铆tulo individual.
Co-Diagnostics, Inc. (CODX) 鞚挫偓鞚� James B. Nelson鞚� 2025-08-13鞐� 125,000欤检潣 鞝滍暅欤检嫕雼渼(RSU)毳� 攵�鞐皼鞎橃姷雼堧嫟. 臧� RSU電� 氩犾姢韺� 鞁� 氤错喌欤� 1欤茧 鞝勴櫂霅橂┌, 鞚措矆 靾橃棳電� 順勳灛 攴�靻嶋悩電� 103,333欤检潣 旮办磮 欤检嫕鞚� 響滌嫓頃橃棳 靾橃棳 頉� 齑� 228,333欤�鞚� 鞁れ 氤挫湢毳� 齑堧灅頃╇媹雼�. RSU鞚� 臧�瓴╈潃 $0.00鞚措┌ 2025-11-23攵�韯� 鞁滌瀾頃� 齑� 6須岇棎 瓯胳硱 霃欖澕頃� 牍勳湪搿� 氩犾姢韺呺悩瓿� 鞚错泟 6臧滌洈毵堧嫟 瓿勳啀霅╇媹雼�. 鞚� 靾橃棳電� 氤搓碃鞚胳澊 臧滌澑 鞛愱博鞙茧 鞝滌稖頃� Form 4鞐� 氤搓碃霅橃棃鞀惦媹雼�.
James B. Nelson, administrateur de Co-Diagnostics, Inc. (CODX), s'est vu accorder 125 000 unit茅s d'actions restreintes (RSU) le 13/08/2025. Chaque RSU se convertit en une action ordinaire lors de l'acquisition, et l'attribution indique 103 333 actions sous-jacentes actuellement imputables, portant le total 脿 228 333 actions d茅tenues 脿 titre b茅n茅ficiaire apr猫s l'attribution. Les RSU ont un prix de 0,00 $ et s'acqui猫rent en six tranches 茅gales 脿 partir du 23/11/2025, puis tous les six mois. L'attribution a 茅t茅 d茅clar茅e dans un formulaire 4 d茅pos茅 par la personne d茅clarante 脿 titre individuel.
James B. Nelson, Vorstand bei Co-Diagnostics, Inc. (CODX), erhielt am 13.08.2025 125.000 Restricted Stock Units (RSUs). Jede RSU wandelt sich bei Vesting in eine Stammaktie um, und die Zuteilung weist derzeit 103.333 zugrundeliegende Aktien aus, wodurch sich nach der Zuteilung insgesamt 228.333 Aktien im wirtschaftlichen Besitz ergeben. Die RSUs haben einen Preis von $0,00 und vesten in sechs gleichen Tranchen beginnend am 23.11.2025, danach alle sechs Monate. Die Zuteilung wurde in einem Formular 4 gemeldet, das die meldende Person als Einzelperson eingereicht hat.
FAQ
What did Co-Diagnostics (CODX) disclose on the Form 4 filed by James B. Nelson?
When do the RSUs granted to James B. Nelson begin to vest?
What is the price and immediate cash impact of the RSU grant?
How many shares will be added to Nelson's ownership if the RSUs fully vest?
Under what plan were the RSUs granted?
